Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals.
Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies.
partner with us
Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines.Interested in a potential collaboration?
Events and conferences
- 19 May 2017 Mereo BioPharma presented at at the American Thoracic Society meeting in Washington, 19-24 May 2017
- 24 Jan 2017 Mereo BioPharma presented at at the Shares Spotlight Evening in London
- 10 Jan 2017 Mereo BioPharma Group plc presented at the 9th Annual Biotech Showcase, 11:00am PST (San Francisco, USA)